Antibodies against protective antigen
The present invention relates to antibodies and related molecules that specifically bind to protective antigen of Bacillus anthracis (PA). Such antibodies have uses, for example, in the prevention and treatment of anthrax and anthrax toxin poisoning. The invention also relates to nucleic acid molecules encoding anti-PA antibodies, vectors and host cells containing these nucleic acids, and methods for producing the same.
1. A composition comprising a monoclonal antibody produced by the cell line contained in ATCC Deposit Number PTA-4796 and a carrier.
2. A pharmaceutical composition comprising the composition of claim 1 , wherein said carrier is a pharmaceutically acceptable carrier.
3. The pharmaceutical composition of claim 2 wherein said pharmaceutically acceptable carrier further comprises sodium citrate, sucrose, glycine, and polysorbate 80.
4. The pharmaceutical composition of claim 2 wherein said composition has a pH of 6.5.
5. A method of treatment of anthrax infection or anthrax toxin poisoning comprising administering the pharmaceutical composition of claim 2 to a human patient.
6. The method of claim 5 wherein said antibody is administered intravenously at 40 mg/kg of the patient's body weight.
7. The method of claim 5 further comprising the administration of an antibiotic.
8. The method of claim 7 wherein the antibiotic is ciprofloxacin.
9. The method of claim 7 wherein the antibiotic is doxycycline.
10. The method of claim 7 wherein the antibiotic is levofloxacin.
11. A method of treating or reducing bacteremia associated with anthrax infection comprising administering the pharmaceutical composition of claim 2 to a human patient.
12. The method of claim 11 wherein said antibody is administered intravenously at 40 mg/kg of the patient's body weight.
13. The method of claim 11 further comprising the administration of an antibiotic.
14. The method of claim 13 wherein the antibiotic is ciprofloxacin.
15. The method of claim 13 wherein the antibiotic is doxycycline.
16. The method of claim 13 wherein the antibiotic is levofloxacin.
17. A monoclonal antibody having the amino acid sequence of the monoclonal antibody produced by the cell line contained in ATCC Deposit Number PTA-4796.
18. A pharmaceutical composition comprising the antibody of claim 17 and a pharmaceutically acceptable carrier.
19. The pharmaceutical composition of claim 18 wherein said pharmaceutically acceptable carrier further comprises sodium citrate, sucrose, glycine, and polysorbate 80.
20. The pharmaceutical composition of claim 18 wherein said composition has a pH of 6.5.
21. A method of treatment of anthrax infection or anthrax toxin poisoning comprising administering the pharmaceutical composition of claim 18 to a human patient.
22. The method of claim 21 wherein said antibody is administered intravenously at 40 mg/kg of the patient's body weight.
23. The method of claim 21 further comprising the administration of an antibiotic.
24. The method of claim 23 wherein the antibiotic is ciprofloxacin.
25. The method of claim 23 wherein the antibiotic is doxycycline.
26. The method of claim 23 wherein the antibiotic is levofloxacin.
27. A method of treating or reducing bacteremia associated with anthrax infection comprising administering the pharmaceutical composition of claim 18 to a human patient.
28. The method of claim 27 wherein said antibody is administered intravenously at 40 mg/kg of the patient's body weight.
29. The method of claim 27 further comprising the administration of an antibiotic.
30. The method of claim 29 wherein the antibiotic is ciprofloxacin.
31. The method of claim 29 wherein the antibiotic is doxycycline.
32. The method of claim 29 wherein the antibiotic is levofloxacin.
33. A pharmaceutical composition comprising:
(a) a monoclonal antibody having the amino acid sequence of the monoclonal antibody produced by the cell line contained in ATCC Deposit Number PTA-4796; and
(b) a pharmaceutically acceptable carrier comprising sodium citrate, sucrose, glycine, and polysorbate 80;
wherein said composition has a pH of 6.5.
34. A method of treatment of anthrax infection or anthrax toxin poisoning comprising administering a pharmaceutical composition to a human patient, wherein said composition comprises:
(a) a monoclonal antibody having the amino acid sequence of the monoclonal antibody produced by the cell line contained in ATCC Deposit Number PTA-4796; and
(b) a pharmaceutically acceptable carrier comprising sodium citrate, sucrose, glycine, and polysorbate 80;
wherein said composition has a pH of 6.5, and wherein said pharmaceutical composition is administered intravenously at 40 mg of said antibody per kg of the patient's body weight.
35. The method of claim 34 further comprising the administration of an antibiotic.
36. The method of claim 35 wherein the antibiotic is ciprofloxacin.
37. The method of claim 35 wherein the antibiotic is doxycycline.
38. The method of claim 35 wherein the antibiotic is levofloxacin.
39. A method of treating or reducing bacteremia associated with anthrax infection comprising administering a pharmaceutical composition to a human patient, wherein said composition comprises:
(a) a monoclonal antibody having the amino acid sequence of the monoclonal antibody produced by the cell line contained in ATCC Deposit Number PTA-4796; and
(b) a pharmaceutically acceptable carrier comprising sodium citrate, sucrose, glycine, and polysorbate 80;
wherein said composition has a pH of 6.5, and wherein said pharmaceutical composition is administered intravenously at 40 mg of said antibody per kg of the patient's body weight.
40. The method of claim 39 further comprising the administration of an antibiotic.
41. The method of claim 40 wherein the antibiotic is ciprofloxacin.
42. The method of claim 40 wherein the antibiotic is doxycycline.
43. The method of claim 40 wherein the antibiotic is levofloxacin.
44. A composition comprising the human monoclonal antibody of claim 17 and a carrier.